Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
, E2 @- @- g- k3 z1 _- V
" w" X- F% D1 ~$ l0 Z
( r. C2 z; R5 y. D9 G1 R$ QSub-category:" W9 b0 e# Z; M8 S( i4 f% T, [
Molecular Targets
8 M6 B# ^( v( ] G8 P) ]& T5 U* Z/ _- w0 \
7 a7 l# _% m2 U o5 n$ W' h' xCategory:2 t k) H1 e1 G2 g
Tumor Biology {) z* F$ x H; _
: _, N5 J6 t# U% g' q; s* k
% h) N/ H/ X$ ?7 ]! W2 aMeeting:
! |! E- |7 I6 c+ F% e5 q" r& [2011 ASCO Annual Meeting % K/ @- e7 g7 \4 f' ^$ I! t
; `* A5 a5 X; T7 v
0 M( C: N' {/ W
Session Type and Session Title:
- C: E4 |) |, C. W1 u" l0 oPoster Discussion Session, Tumor Biology
% D6 j/ u2 W9 l. c- D/ Q
: y# y0 _* |# i1 l6 u1 D- u* q7 }+ u* ~$ c$ }- E9 t3 c
Abstract No:1 z# I- m/ N8 Q! m2 U% x* L9 Q
10517
! L; l' Q9 C5 {9 k: `( l/ q
% l7 I4 k: q& }& w! N# H
- Z! N' J* B3 M7 L8 S: @Citation:$ T5 L- b6 z0 g6 r# l
J Clin Oncol 29: 2011 (suppl; abstr 10517)
, E' L6 l5 T3 n" G8 H, ~) y: \( X/ \7 e! l0 S0 e* R6 _
' ?0 @) w1 N3 O9 s9 dAuthor(s):, a2 H! x! A: k6 a+ r
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
; a8 {5 C* P% N- {3 D& A o) L1 a- H% s' y. K, g7 R5 K/ J
3 P+ t4 L+ f0 u* z; D
: `" t5 m* _! m- f/ @- ]+ j2 Z
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings./ _4 s1 T( \) ^0 x+ K
! C1 Q8 T7 c4 u
Abstract Disclosures
4 q" y) S( O5 d" S( d' P
' E! ?+ O m% J) V& e# RAbstract:& d m$ O3 a, h5 v1 w. }$ ?9 r
4 F5 L$ }" N7 ^& n1 r
, h- Q) f! C# ~/ ^( }' Z
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
7 e% P: ? w) g1 K
" `" x" @0 v* ?2 C _' } 1 D+ s2 U9 S1 Z! O7 O& A* B* q
|
- g' A& i2 k( c- m* a& j
显身卡
